arrow
N

Norbert Kraut

Boehringer Ingelheim
H指数:41
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer
MABS
IF7.3
2024-12-090
OAAI
KRASmulti inhibitor BI 3706674 shows efficacy in KRAS-driven preclinical models of cancer that supports clinical testing in patients with tumors harboring KRASG12V mutations and KRAS wild-type amplifications
2024-10-010
PRE
Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2-p53 Antagonist Suitable for Intermittent Dose Schedules
2024-09-112
OAAI
Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance

共靶向SOS1通过解决内在和获得性耐药增强KRASG12C抑制剂的抗肿瘤作用

2024-08-051
OA
Development and characterisation of KRASmulti inhibitors for the treatment of KRAS mutant pancreatic ductal adenocarcinoma
2024-01-160
PRE
Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

Pan-kras抑制剂禁用致癌信号传导和肿瘤生长

Nature
IF48.5
2023-05-310
OAAI
Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition
2023-03-018
OAAI
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling

发现对HER2外显子20插入驱动的肿瘤有效的和选择性的HER2抑制剂,其保留野生型EGFR信号传导

2022-07-2615
PRE
One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS

一个原子就能改变一切: 在SOS1和KRAS之间进门

2021-03-1540
PRE
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition

BI-3406是一种有效的选择性SOS1-KRAS相互作用抑制剂,通过联合MEK抑制对KRAS驱动的癌症有效

2021-01-06276
OAAI
Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist
2021-01-0523
OAAI